Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
WorldTrips, based in Carmel, Indiana, a leading provider of global travel medical insurance, is excited to announce the launch of its latest travel medical product, Atlas JapanSecure. This new ...
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...